Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study

Circ Arrhythm Electrophysiol. 2012 Feb;5(1):155-62. doi: 10.1161/CIRCEP.111.966804. Epub 2012 Jan 6.

Abstract

Background: Several cardiovascular risk factors have been associated with the risk of atrial fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid levels and lipid-lowering medication use with AF risk.

Methods and results: We analyzed 13 969 participants (25% African American, 45% men) free of AF at baseline from the Atherosclerosis Risk in Communities study. Fasting high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), triglycerides, and total cholesterol were measured at baseline (1987-1989) and each of 3 follow-up visits. The incidence of AF was ascertained through 2007. The association of the use of statins and other lipid-lowering medications with AF was estimated in 13 044 Atherosclerosis Risk in Communities participants attending visit 2 (1990-1992), adjusting for covariates from the previous visit. During a median follow-up of 18.7 years, there were 1433 incident AF cases. Multivariable hazard ratios (HRs) and 95% CIs of AF associated with a 1-SD increase in lipid levels were as follows: HDLc, 0.97 (0.91-1.04); LDLc, 0.90 (0.85-0.96); total cholesterol, 0.89 (0.84-0.95); and triglycerides, 1.00 (0.96-1.04). Participants taking lipid-lowering medications had an adjusted HR (95% CI) of AF of 0.96 (0.82-1.13) compared with those not taking medications, whereas those taking statins had an adjusted HR of 0.91 (0.66-1.25) compared with those taking other lipid-lowering medications.

Conclusions: Higher levels of LDLc and total cholesterol were associated with a lower incidence of AF. However, HDLc and triglycerides were not independently associated with AF incidence. No association was found between the use of lipid-lowering medications and incident AF.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Atherosclerosis / blood*
  • Atherosclerosis / complications
  • Atherosclerosis / drug therapy
  • Atrial Fibrillation / blood
  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / etiology
  • Biomarkers / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Incidence
  • Lipids / blood*
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Risk Assessment / methods*
  • Risk Factors
  • United States / epidemiology

Substances

  • Biomarkers
  • Hypolipidemic Agents
  • Lipids